Title: 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma
Authors: Mackintosh, C ×
Ordóñez, J L
García-Domínguez, D J
Sevillano, V
Llombart-Bosch, A
Szuhai, K
Scotlandi, K
Alberghini, M
Sciot, Raf
Sinnaeve, F
Hogendoorn, P C W
Picci, P
Knuutila, S
Dirksen, U
Debiec-Rychter, Maria
Schaefer, K-L
de Álava, E #
Issue Date: Mar-2012
Publisher: Scientific & Medical Division, Macmillan Press
Series Title: Oncogene vol:31 issue:10 pages:1287-1298
Article number: 10.1038/onc.2011.317
Abstract: Despite extensive characterization of the role of the EWS-ETS fusions, little is known about secondary genetic alterations and their clinical contribution to Ewing sarcoma (ES). It has been demonstrated that the molecular structure of EWS-ETS lacks prognostic value. Moreover, CDKN2A deletion and TP53 mutation, despite carrying a poor prognosis, are infrequent. In this scenario identifying secondary genetic alterations with a significant prevalence could contribute to understand the molecular mechanisms underlying the most aggressive forms of ES.We screened a 67 ES tumor set for copy number alterations by array comparative genomic hybridization. 1q gain (1qG), detected in 31% of tumor samples, was found markedly associated with relapse and poor overall and disease-free survival and demonstrated a prognostic value independent of classical clinical parameters. Reanalysis of an expression dataset belonging to an independent tumor set (n=37) not only validated this finding but also led us to identify a transcriptomic profile of severe cell cycle deregulation in 1qG ES tumors. Consistently, a higher proliferation rate was detected in this tumor subset by Ki-67 immunohistochemistry. CDT2, a 1q-located candidate gene encoding a protein involved in ubiquitin ligase activity and significantly overexpressed in 1qG ES tumors, was validated in vitro and in vivo proving its major contribution to this molecular and clinical phenotype. This integrative genomic study of 105 ES tumors in overall renders the potential value of 1qG and CDT2 overexpression as prognostic biomarkers and also affords a rationale for the application of already available new therapeutic compounds selectively targeting the protein-ubiquitin machinery.Oncogene advance online publication, 8 August 2011; doi:10.1038/onc.2011.317.
ISSN: 0950-9232
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Department of Human Genetics - miscellaneous
Translational Cell & Tissue Research
Laboratory for Genetics of Malignant Disorders
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Mackintosh Oncogene 2012.pdfpublisher's version pdf Published 948KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science